In situ antigenic modulation of human graft-infiltrating T cells is induced by OKT3 treatment.
Caillat-Zucman
S
S
Inserm U 25, Hôpital Necker, Paris, France.
Legendre
C
C
Noel
L H
LH
Bach
J F
JF
Kreis
H
H
Chatenoud
L
L
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D015703:Antigens, CD / Q000032:analysis; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis; D017252:CD3 Complex; D005455:Fluorescent Antibody Technique; D006801:Humans; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation / Q000276:immunology*; D008212:Lymphocyte Depletion; D016853:Muromonab-CD3; D011948:Receptors, Antigen, T-Cell / Q000032:analysis; D013601:T-Lymphocytes / Q000276:immunology* / Q000473:pathology; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D016853:Muromonab-CD3; D011948:Receptors, Antigen, T-Cell